{"id":502813,"date":"2022-12-13T13:31:41","date_gmt":"2022-12-13T12:31:41","guid":{"rendered":"http:\/\/intervacc.se\/?p=502813"},"modified":"2022-12-13T13:31:41","modified_gmt":"2022-12-13T12:31:41","slug":"strangvac-a-vaccine-against-equine-strangles-released-for-sales-in-italy","status":"publish","type":"post","link":"https:\/\/intervacc.se\/en\/strangvac-a-vaccine-against-equine-strangles-released-for-sales-in-italy\/","title":{"rendered":"Strangvac, a vaccine against equine strangles released for sales in Italy"},"content":{"rendered":"
\n

Stockholm, December 13th, 2022 – Intervacc AB (publ) announces today that the first batch of Strangvac\u00ae<\/sup>, a vaccine against the highly contagious bacterial equine disease Strangles, has been released for sale in Italy. Dechra Pharmaceuticals PLC distributes the vaccine in Italy and in a number of other European countries.<\/p>\n<\/div>\n\n\n

\u201cThe first batch of Strangvac\u00ae<\/sup> for Italy has now been released. This means that sales of Strangvac\u00ae in Italy can begin\u201d<\/em>, explains Andreas Johansson, Logistics Manager at Intervacc.<\/p>\n\n\n\n

\u201cStreptococcus equi causes significant suffering in populations of horses in Italy. I have studied the strains recovered from Italian horses as they cause disease to better understand how this pathogen spreads. Therefore, I am delighted that we now have an additional tool with which to help keep our horses safe,\u201d<\/em> says Dr. Silvia Preziuso at the Universit\u00e0 di Camerino.<\/p>\n\n\n\n

“Strangvac\u00ae<\/sup> is approved for sale and marketing in the EU as well as the UK and Norway. Strangvac\u00ae has been launched in Sweden, Denmark, the UK, France, Germany, the Benelux region, Austria, Ireland, Poland and now also in Italy. Outbreaks of equine strangles occur regularly and the disease cause great suffering and economic cost in the region and across Europe. Italy is an important equine market, and this is significant milestone for our continued launch around Europe.\u201d<\/em> comments Andreas Andersson, CEO of Intervacc.<\/p>\n\n\n\n

For more information please contact:<\/strong><\/p>\n\n\n\n

Andreas Andersson, CEO
Phone: +46-8-120 10 601, cell +46-73-335 99 70
E-mail: andreas.andersson@intervacc.com<\/p>\n\n\n\n

The information was submitted for publication, through the agency of the contact person set out above on December 13, 2022, 13.30 CET.<\/em><\/p>\n\n\n\n

About Intervacc<\/strong><\/p>\n\n\n\n

Intervacc AB is a Swedish company within animal health developing vaccines for animals. The Company’s vaccine and vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company\u00b4s research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB as Certified Adviser.<\/p>\n\n\n\n

About equine strangles<\/strong><\/p>\n\n\n\n

Equine strangles, caused by Streptococcus equi<\/em>, is the most frequently diagnosed infectious disease of horses, and affects horses all over the world with one exception Iceland where the import of horses is prohibited. Streptococcus equi<\/em> invades the lymph nodes of head and neck, causing them to swell and form abscesses that can literally strangle, in around 2% of cases, the horse to death. Some of the horses that recover from strangles remain persistently infected. These apparently healthy animals shed bacteria into the environment and spread the disease to other horses with which they come into contact.<\/p>\n\n\n\n

Contact information for Certified Adviser<\/strong><\/p>\n\n\n\n

Eminova Fondkommission AB
E-mail: adviser@eminova.se, Phone: +46 (0)8 \u2013 684 211 10<\/p>\n","protected":false},"excerpt":{"rendered":"

Stockholm, December 13th, 2022 – Intervacc AB (publ) announces today that the first batch of Strangvac\u00ae, a vaccine against the […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false},"categories":[27],"tags":[],"_links":{"self":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/posts\/502813"}],"collection":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/comments?post=502813"}],"version-history":[{"count":3,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/posts\/502813\/revisions"}],"predecessor-version":[{"id":502830,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/posts\/502813\/revisions\/502830"}],"wp:attachment":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/media?parent=502813"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/categories?post=502813"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/tags?post=502813"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}